vTv Therapeutics
VTVT
Market cap $34.8M

14.31 USD

-0.28

1.92%

At close Oct 7, 4:00 PM EDT

1 day

-1.92%

5 days

5.92%

1 month

-5.54%

3 months

-20.94%

6 months

-42.76%

Year to date

32.50%

1 year

-22.52%

5 years

-76.31%

About: vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.

Employees: 16

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0.56% more ownership

Funds ownership: 13.77% [Q1] → 14.33% (+0.56%) [Q2]

0% more funds holding

Funds holding: 19 [Q1] → 19 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

22% less capital invested

Capital invested by funds: $7.87M [Q1] → $6.15M (-$1.72M) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for VTVT.

See Analyst Rankings

Financial journalist opinion

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

Screened first patient in cadisegliatin pivotal trial for type 1 diabetes (T1D); working to resolve clinical hold Expanded Newsoara Biopharma license agreement for PDE4 inhibitor HPP737 to a global license effective upon payment of the $20 million upfront fee HIGH POINT, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today reported financial results for the second quarter ended June 30, 2024, and provided an update on recent corporate developments.

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

Why Is vTv Therapeutics (VTVT) Stock Down 46% Today?

VTv Therapeutics (NASDAQ: VTVT ) stock is falling hard on Monday after the Food and Drug Administration (FDA) placed a clinical hold on its cadisegliatin clinical program. According to a news release from the company, that hold includes its TT1 Phase 3 trial in type 1 diabetes.

Why Is vTv Therapeutics (VTVT) Stock Down 46% Today?

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 Phase 3 trial in type 1 diabetes. Cadisegliatin is an oral, liver selective, glucokinase activator that has been well-tolerated in over 500 subjects to date with up to six months of treatment.

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

WESTON, Fla. , May 28, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that Cantex's azeliragon, a well-tolerated once-a-day pill that inhibits "RAGE" (the receptor for advanced glycation end products), will be featured in four abstracts at this year's 2024 ASCO Annual Meeting to be held in Chicago.

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

HIGH POINT, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate developments.

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

Podium presentation will include clinical updates from the Company's Phase 2 clinical trials investigating azeliragon, in combination with radiation therapy with or without temozolomide, in newly diagnosed glioblastoma WESTON, Fla., March 19, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that the Company's CEO, Stephen Marcus, M.D.

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

HIGH POINT, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided an update on recent corporate developments.

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

The Top 3 Healthcare Stocks to Buy on Weakness in 2024

Healthcare stocks have started the year off very strongly, propelled by excitement about weight loss drugs and investments by Nvidia (NASDAQ: NVDA ). The sector is also getting a lift from the U.S. Federal Reserve's decision to stop raising rates and its suggestions that it will cut rates later this year.

The Top 3 Healthcare Stocks to Buy on Weakness in 2024

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

HIGH POINT, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced the submission of the study protocol to the FDA for the Company's first Phase 3 trial evaluating the safety and efficacy of its lead candidate, cadisegliatin, in adults diagnosed with T1D.

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

See News Rankings

Charts implemented using Lightweight Charts™